Objective validity of patient‐reported symptoms in aspirin‐exacerbated respiratory disease patients

2021 ◽  
Author(s):  
Pooja P. Patel ◽  
Jing Cui ◽  
Katherine N. Cahill ◽  
Tanya M. Laidlaw
Keyword(s):  
Respiratory Disease ◽  
Aspirin Exacerbated Respiratory Disease ◽  
Patient Reported ◽  
Objective Validity

scholarly journals Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease

2021 ◽  
Vol 42 (2) ◽  
pp. 136-141
Author(s):  
Auddie M. Sweis ◽  
Tran B. Locke ◽  
Kevin I. Ig-Izevbekhai ◽  
Theodore C. Lin ◽  
Ankur Kumar ◽  
...  
Keyword(s):  
Respiratory Disease ◽  
Endoscopic Sinus Surgery ◽  
Test Score ◽  
Aspirin Therapy ◽  
Sinus Surgery ◽  
Secondary Outcome ◽  
Persistent Symptoms ◽  
Aspirin Exacerbated Respiratory Disease ◽  
Patient Reported ◽  
The Mean

Background: Aspirin therapy and/or type 2 (T2) biologics are used in the management of aspirin-exacerbated respiratory disease (AERD). Objective: To identify the number of patients with AERD who tolerated aspirin therapy, yet due to persistent symptoms, incorporated T2 biologic management. Methods: A retrospective review was performed between July 2016 and June 2019. Patients with AERD and who underwent endoscopic sinus surgery (ESS), aspirin desensitization (AD), and at least 6 months of aspirin therapy (ATAD) after AD, and who remained biologic-naive up through this timepoint were included in the study. Introduction of a T2 biologic while on ATAD was the primary outcome. The secondary outcome was a change in a validated patient-reported outcome measure for chronic rhinosinusitis score between the postoperative predesensitization timepoint, and the 6-month postdesensitization timepoint, presented as means and compared by using the Student's t-test. Results: A total of 103 patients met inclusion criteria. Two patients (1.9%) ultimately supplemented ATAD with a T2 biologic. The mean outcomes measure test score after 6 months of ATAD for patients who received biologics was 40.5 versus 15 in those who did not receive biologics (p = 0.02). The mean differences between the postoperative predesensitization test score and the 6-month postdesensitization test score for patients who went on to receive biologics was an increase of 13 versus a decrease of 10 for those patients who did not receive biologics (p = 0.12). Conclusion: ESS, coupled with AD and ATAD, was successful in the long-term management of the majority of the patients with AERD, which rarely required the incorporation of T2 biologics. Patient questionnaires, such as outcomes measure test score, may identify aspirin therapy failures and help guide the practitioner in deciding when to introduce T2 biologics into the patient's treatment regimen.

Bedeutung der allergologischen Abklärung bei Asthma und COPD

2014 ◽  
Vol 71 (5) ◽  
pp. 267-274
Author(s):  
Judith A. Schneider Spence ◽  
Andreas J. Bircher ◽  
Kathrin Scherer Hofmeier
Keyword(s):  
Respiratory Disease ◽  
Asthma Bronchiale ◽  
Aspirin Exacerbated Respiratory Disease ◽  
Work Up

Während eine allergologische Abklärung im Work-Up eines Asthma bronchiale inbegriffen sein sollte, wird die chronisch obstruktive Pneumopathie nicht spontan mit einer atopischen Diathese in Zusammenhang gebracht. Anamnese, Klinik, das Vorhandensein weiterer atopischer Krankheiten sowie Prickteste und die serologische Messung von spezifischen IgE-Antikörpern geben Hinweise auf eine allergische Genese einer akuten oder chronischen Lungenkrankheit. Der Stickoxidwert in der Ausatemluft (FeNO-Messung) kann durch die Infiltration von Eosinophilen in die Bronchialwand beim allergischen Phänotyp des Asthma bronchiale erhöht sein (TH2-gewichteter Phänotyp). Eine Abhängigkeit der Beschwerden vom Arbeitsplatz muss evaluiert werden. Neben dem allergischen Typ des Asthma bronchiale soll auch an eine Aspirin-exacerbated-respiratory disease (AERD) gedacht werden. Aufgrund der überlappenden pathophysiologischen Grundlagen und der Symptomatik zwischen Asthma bronchiale und der chronisch obstruktiven Pneumopathie ist die Zuweisung zum Allergologen allenfalls auch bei einem COPD-Patienten indiziert.

Inflammatory heterogeneity in aspirin-exacerbated respiratory disease

2020 ◽  
Author(s):  
William C. Scott ◽  
Katherine N. Cahill ◽  
Ginger L. Milne ◽  
Ping Li ◽  
Quanhu Sheng ◽  
...  
Keyword(s):  
Respiratory Disease ◽  
Aspirin Exacerbated Respiratory Disease
Sign in / Sign up

Export Citation Format

Share Document